10
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine

      review-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The recent rapid development of COVID-19 vaccines offers hope in addressing the worst pandemic in a hundred years. However, many countries in the Global South face great difficulties in accessing vaccines, partly because of restrictive intellectual property law. These laws exacerbate both global and domestic inequalities and prevent countries from fully realising the right to health for all their people. Commodification of essential medicines, such as vaccines, pushes poorer countries into extreme debt and reproduces national inequalities that discriminate against marginalised groups. This article explains how a decolonial framing of human rights and public health could contribute to addressing this systemic injustice. We envisage a human rights and global health law framework based on solidarity and international cooperation that focuses funding on long-term goals and frees access to medicines from the restrictions of intellectual property law. This would increase domestic vaccine production, acquisition and distribution capabilities in the Global South.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: not found
          • Article: not found

          Developing Covid-19 Vaccines at Pandemic Speed

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Drug development for neglected diseases: a deficient market and a public-health policy failure.

            There is a lack of effective, safe, and affordable pharmaceuticals to control infectious diseases that cause high mortality and morbidity among poor people in the developing world. We analysed outcomes of pharmaceutical research and development over the past 25 years, and reviewed current public and private initiatives aimed at correcting the imbalance in research and development that leaves diseases that occur predominantly in the developing world largely unaddressed. We compiled data by searches of Medline and databases of the US Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products, and reviewed current public and private initiatives through an analysis of recently published studies. We found that, of 1393 new chemical entities marketed between 1975 and 1999, only 16 were for tropical diseases and tuberculosis. There is a 13-fold greater chance of a drug being brought to market for central-nervous-system disorders or cancer than for a neglected disease. The pharmaceutical industry argues that research and development is too costly and risky to invest in low-return neglected diseases, and public and private initiatives have tried to overcome this market limitation through incentive packages and public-private partnerships. The lack of drug research and development for "non-profitable" infectious diseases will require new strategies. No sustainable solution will result for diseases that predominantly affect poor people in the South without the establishment of an international pharmaceutical policy for all neglected diseases. Private-sector research obligations should be explored, and a public-sector not-for-profit research and development capacity promoted.
              Bookmark
              • Record: found
              • Abstract: not found
              • Book: not found

              Decolonization is not a metaphor

                Bookmark

                Author and article information

                Journal
                BMJ Glob Health
                BMJ Glob Health
                bmjgh
                bmjgh
                BMJ Global Health
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2059-7908
                2021
                12 July 2021
                12 July 2021
                : 6
                : 7
                : e006169
                Affiliations
                [1 ]departmentWarwick Law School , University of Warwick , Coventry, UK
                [2 ]departmentDalla Lana School of Public Health , University of Toronto , Toronto, Ontario, Canada
                [3 ]International Commission of Jurists , Johannesburg, South Africa
                [4 ]Center for Health, Human Rights and Development , Kampala, Uganda
                [5 ]departmentSchool of Law , Makerere University , Kampala, Uganda
                [6 ]departmentDepartment of Public Policy , University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, USA
                Author notes
                [Correspondence to ] Dr Sharifah Sekalala; sharifah.sekalala@ 123456warwick.ac.uk
                Author information
                http://orcid.org/0000-0002-5434-5245
                http://orcid.org/0000-0002-4200-9359
                Article
                bmjgh-2021-006169
                10.1136/bmjgh-2021-006169
                8277484
                34253631
                2120c256-f923-4dcf-82ef-ea014cf1af30
                © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 30 April 2021
                : 11 June 2021
                Categories
                Analysis
                1506
                2474
                Custom metadata
                unlocked

                covid-19,vaccines,health economics,treatment
                covid-19, vaccines, health economics, treatment

                Comments

                Comment on this article